Novo Nordisk’s NVO shares gained 8.5% on Friday after the company announced positive top-line data from an early to mid-stage ...

NPA chairman Nick Kaye told the PA news agency that while obesity is "one of the biggest challenges facing" the UK, they are ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Results from the STEP UP trial show that a high-dose formulation of Wegovy can significantly increase the weight loss effects the drug is known for. Novo Nordisk has announced topline results from the ...

As a result, there’s no standard recommended dose of coconut oil for the treatment ... this would be 200 calories from saturated fat per day. To put this into perspective, one tablespoon ...

Junshi has conducted more than 40 company-sponsored clinical studies of the therapy. Credit: PeopleImages.com – Yuri A/Shutterstock. Shanghai Junshi Biosciences and its subsidiary TopAlliance ...

Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and tolerable. In the Phase IIIb STEP UP trial, 7.2mg Wegovy demonstrated statistically ...

Novo Nordisk has commenced the STEP UP and STEP UP T2D trials to explore the efficacy of semaglutide 7.2mg. Credit: © 2025 Novo Nordisk A/S. Novo Nordisk’s high ...

New data obtained has found cases soared over the four weeks to the end of November, with an extra 118 hospitalisations recorded by the MHRA - a rise described by senior doctors as 'alarming'.

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Patients who took triple the normal dose of semaglutide, the main ingredient in Wegovy, for 72 weeks lost 20.7% of their body weight, Novo said Friday in a statement . That compared with a 17.5% ...

Patients who took triple the normal dose of semaglutide, the main ingredient in Wegovy, for 72 weeks lost 20.7% of their body weight, Novo said Friday in a statement. That compared with a 17.5% ...